Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient \> 18 years old
Histologically confirmed diagnosis of melanoma
Previously treated or previously untreated metastatic melanoma by AJCC staging criteria
Presence of an index lesion \> 1 cm amenable to hypofractionated radiotherapy and at least one other additional lesion that can be followed for response using RECIST criteria
ECOG Performance status 0 or 1
Signed informed consent document
Ability to tolerate stereotactic body radiation therapy (e.g. lie flat and hold position for treatment)
You may not be if
Prior systemic therapy within 14 days of study enrollment. Patients must be adequately recovered from prior systemic therapy side effects as deemed by the PI.
Clinical contraindication to stereotactic body radiotherapy (e.g. active systemic sclerosis, active inflammatory bowel disease if bowel is within target field, etc)
Presence or history of central nervous system metastasis (including brain)
Long-term use of systemic corticosteroids
Prior RT that precludes the delivery of hypofractionated radiotherapy
